This study is a phase 2, open-label extension study of 12 mg Proellex for 2 treatment cycles,
each with a 16 week active dosing period. Endometriosis pain, dysmenorrhea, non-menstrual
pelvic pain and dyspareunia (BBSS) as well as use of pain medications, and vaginal bleeding
intensity will be recorded using an electronic diary and Visual Analog Scale (VAS) pain
assessment will be utilized. All subjects will have completed an Off-Drug Interval (ODI)
prior to starting treatment. Visit 1 will be scheduled within a week before the next expected
menses (+/- 2 days), following the off-drug interval. Subjects will receive 2 cycles of
treatment separated by an off-drug interval (ODI), after which they will be followed until
menses has returned. During the follow-up period subjects will continue to record study
information in the electronic diary. The final follow-up visit will be scheduled after blood
flow has stopped.